Survival and prognostic factors in patients with oral squamous cell carcinoma

Andressa Kelly Alves Ferreira 1, Sérgio Henrique Gonçalves de Carvalho 1,2, Ana Flávia Granville-Garcia 3, Dmitry José de Santana Sarmento 2, Gustavo Gomes Agripino 2, Mauro Henrique Nogueira Guimarães de Abreu 4, Maria Cecilia Freire de Melo 2, Arnaldo de França Caldas Jr 1, Gustavo Pina Godoy 1,5

1 Dentistry postgraduate program, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil
2 Department of Dentistry, Universidade Estadual da Paraíba (UEPB), Araruna, Paraíba, Brazil
3 Dentistry postgraduate program, Universidade Estadual da Paraíba (UEPB), Campina Grande, Paraíba, Brazil
4 Department of Community and Preventive Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
5 Department of Pathology, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil

Correspondence:
Department of Pathology
Avenida Professor Moraes Rego, 1235
CEP 50670-901, Recife, Pernambuco, Brazil
gruiga@hotmail.com

Received: 15/08/2020
Accepted: 24/09/2020

Abstract
Background: This study aimed to evaluate sociodemographic and clinical factors influencing overall survival (OS) in patients with oral squamous cell carcinoma (OSCC).
Material and Methods: Medical charts of 547 patients with OSCC from a public hospital in northeastern Brazil seen between 1999 and 2013 were evaluated. Survival analysis was performed using the Kaplan-Meier method. The influence of age, sex, ethnicity, clinical stage, anatomical location, type of treatment, and comorbidities on the patients’ prognosis was evaluated. Cox proportional hazards regression model was used to identify independent prognostic factors.
Results: The 5-year OS was 39%. Multivariate analysis showed that age < 40 years (HR = 2.20; 95%CI: 1.02-4.72) and a single treatment modality (HR = 1.91; 95%CI: 1.37-2.67) were associated with a poor prognosis, while early clinical stage resulted in better outcomes (HR = 0.38; 95%CI: 0.25-0.58).
Conclusions: OSCC patients in advanced clinical stages, diagnosed at a younger age, and submitted to a single therapeutic modality have a poorer prognosis.

Key words: Head and neck cancer, oral cancer, oral squamous cell carcinoma, survival, prognosis.
Introduction

Oral squamous cell carcinoma (OSCC) is the most common neoplasm of the oral cavity, which accounts for about 95% of all cases of head and neck cancers. This neoplasm has a multifactorial etiology and commonly affects men between the sixth and seventh decades of life with smoking and drinking habits (1,2).

An increase in oral cavity cancer cases is observed in Brazil. Recent reports estimate that approximately 23,000 new oral cavity and oropharyngeal cancer cases are expected for each year of the 2020-2022 triennium (3).

Despite the advances made in diagnosis and treatment, the prognosis of OSCC continues to be unfavorable, with low 5-year survival rates being reported in the literature. OSCC thus represents an important public health problem. In 2018, about 177,000 deaths related to lip and oral cavity cancer occurred worldwide (4).

Several variables have been pointed out as prognostic factors in individuals with OSCC such as age, gender, and socioeconomic factors, as well as clinical and pathological features of the tumor, including anatomical location, histopathological grading, and treatment modality. However, results regarding the association between survival time and prognostic and predictive factors remain unclear (5,6).

Considering the importance of providing updated information about predictive factors and prognosis of OSCC for health planning and management, this study aims to estimate the survival of patients with OSCC and to evaluate the influence of sociodemographic and clinical features on patient survival time.

Material and Methods

- Ethical aspects

This study was conducted in full accordance with the World Medical Association's Declaration of Helsinki as revised in 2013 and received approval from the Human Research Ethics Committee of the State University of Paraíba (Brazil).

- Sample and data collection

This study included data obtained from the medical charts of 547 patients with pathologically confirmed OSCC who were treated from 1999 to 2013 at an oncology referral center in the state of Paraíba, northeastern Brazil. The patient charts were reviewed to identify the sociodemographic profile, tumor characteristics, and proposed treatment.

- Variables

The following sociodemographic variables were obtained: gender, ethnicity (white or non-white), age (≤ 40 and > 40 years), habits of smoking and/or alcohol consumption, and the existence of systemic and/or oral comorbidities. Systemic comorbidities included hypertension, diabetes, depression, sexually transmitted infections, and hematological, hepatic, pulmonary, gastrointestinal, renal and cardiac pathologies. Oral comorbidities comprised xerostomia, mucositis, limited mouth opening, dysphonia, dysgeusia, dysphagia, and candidiasis. This information was assessed in multiprofessional records.

The anatomical site of the tumor was categorized according to ICD-10 (7) into lip (C00-0 to C00-2) and oral cavity (C00-3 to C10, except 07-08). The stage of disease was determined according to the American Joint Committee on Cancer (AJCC) staging criteria (7th Cancer Staging Manual), corresponding to early (I and II) and advanced stages (III and IV) (8).

Treatment was classified as single therapy when surgery, radiotherapy or chemotherapy was applied alone, or as combination therapy when one therapy was used in combination with one or more of the aforementioned modalities.

Overall survival (OS) was calculated from the date of histopathological diagnosis of primary OSCC to the date of death or last follow-up.

- Statistical analysis

Descriptive analysis was performed for sample characterization. The probability of survival was estimated using the Kaplan-Meier method. Cox models were used to estimate the unadjusted and adjusted hazard ratio (HR, 95% CI). Each covariate was included separately in the Cox model and the unadjusted HR (95% CI) was estimated. Covariates with a p-value of less than 0.25 were included in the final Cox model and only variables with a p-value less than 0.05 remained. Graphical analysis was used to evaluate the adequacy of the variables for the assumption of proportional risks. All statistical analyses were performed using the SPSS software for Windows, version 23.0 (SPSS Inc., Chicago, IL, USA).

Results

A total of 547 patients were diagnosed with primary OSCC between 1999-2013 at the reported cancer center. The patient characteristics are summarized in Table 1. Most patients were male (63.7%), older than 40 years (97.4%), and white (61.1%). Systemic and oral comorbidities were found in only 36.6% and 27.8% of the patients, respectively. A high percentage of patients (74.4%) had a history of smoking and/or alcohol consumption.

The most common anatomical site of OSCC was the oral cavity (88.1%) and most tumors were diagnosed in advanced stages (54.8%). Regarding treatment modality, combination therapies were the most common in the sample (56.7%).

The 5-year OS of this sample was 39% and the mean and median time of cancer survival was 56 and 31 months, respectively. Fig. 1 shows the Kaplan-Meier survival curve of the patients evaluated.
Multivariate analysis revealed that, among the variables studied, age ($p = 0.044$), clinical stage ($p < 0.001$), and treatment ($p < 0.001$) were covariates associated with survival time (Table 2). The results show that individuals aged up to 40 years had a more than two-fold higher risk of death than older patients (HR = 2.20; 95%CI 1.02-4.72). Patients in early clinical stages had a lower risk of death compared to advanced stages (HR = 0.38; 95%CI 0.25-0.58). The type of treatment also influences the risk of death. Patients treated with a single therapeutic approach were almost twice as likely to die from OSCC (HR = 1.91; 95%CI 1.37-2.67).

| Variable                        | Unadjusted HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value |
|---------------------------------|------------------------|---------|-----------------------|---------|
| Sex (n=547)                     | Female                 | 1       |                       |         |
|                                 | Male                   | 0.94 (0.69-1.28) | 0.704               |         |
| Age (n=547)                     | > 40 years             | 1       |                       |         |
|                                 | ≤ 40 years             | 1.85 (0.87-3.95) | 0.110               | 2.20 (1.02-4.72) | 0.044 |
| Ethnic group (n=547)            | Non-white              | 1       |                       |         |
|                                 | White                  | 1.04 (0.77-1.42) | 0.789               |         |
| Systemic comorbidities (n=512)* | No                     | 1       |                       |         |
|                                 | Yes                    | 1.00 (0.73-1.37) | 0.998               |         |
| Oral comorbidities (n=460)*     | No                     | 1       |                       |         |
|                                 | Yes                    | 1.02 (0.71-1.46) | 0.937               |         |
| Smoking/alcohol consumption (n=533)* | No         | 1       |                       |         |
|                                 | Yes                    | 1.65 (1.11-2.45) | 0.013               |         |
| Anatomical site (n=547)         | Oral cavity            | 1       |                       |         |
|                                 | Lip                    | 0.67 (0.40-1.12) | 0.129               |         |
| Clinical Stage (n=445)*         | Advanced (E3, E4)      | 1       |                       |         |
|                                 | Early (E1, E2)         | 0.40 (0.26-0.60) | <0.001              | 0.38 (0.25-0.58) | <0.001 |
| Treatment (n=547)               | Single treatment       | 1       |                       |         |
|                                 | Combination therapy    | 1.61 (1.20-2.16) | 0.002               | 1.91 (1.37-2.67) | <0.001 |

CI = confidence interval; HR = hazard ratio. * Variable with missing data.
Discussion
The 5-year OS rate of the current study can be considered low when compared to patients with OSCC in other reports (6,09). Furthermore, the findings showed that age ≤ 40 years and a single treatment modality were predictors of poorer overall survival, while early clinical stages provided better outcomes in OSCC patients. Regarding age, despite the low prevalence of young patients in the sample, the findings showed a higher mortality risk among younger individuals, in agreement with earlier studies (10,11). One factor linked to poorer outcomes in younger patients is a different and more aggressive behavior of the lesions, which could be associated with genetic alterations (12,13). Younger patients are also more likely to have lymphatic metastasis at the time of diagnosis and to have poorly differentiated OSCC, which may result in treatment failure and higher recurrence rates (14,15). Furthermore, OSCC in younger individuals is commonly found at the base of the tongue and oropharynx, which are subsites frequently associated with a poor prognosis (10,14). In contrast, other authors found poorer survival in older individuals. This fact has been associated with comorbidities, which usually limit treatment choices and enhance the likelihood of complications (16,17). Evidence also highlights the increasing association between HPV infection and oropharyngeal cancers in younger patients, with HPV-positive cancers presenting a better treatment response and survival than HPV-unrelated tumors (18).

In the present study, no statistically significant associations were found between survival rates and gender or ethnicity. Other studies identified a poorer prognosis of OSCC in male individuals compared to females (09,16). The higher prevalence and mortality from OSCC in men are usually linked to their increased exposure to risk factors such as tobacco and alcohol consumption. Furthermore, the frequency of health-seeking behaviors tends to be lower in male patients, a fact that can delay the diagnosis and treatment initiation (19). Regarding ethnicity, studies found no correlation between ethnic/racial characteristics and survival in OSCC when adjusted for parameters such as tumor characteristics and treatment (20,21). However, some evidence indicates that ethnicity may play an important role in OSCC survival, with the observation of lower survival rates among black individuals (22). This poorer prognosis has been attributed to lower socioeconomic status and educational levels among blacks when compared to whites, which tend to highly expose this group to more risk factors and hinder access to health services (23). Moreover, black patients had an increased risk of presenting locally advanced and untreatable oral tumors (24).

Cox regression analysis indicated that advanced clinical stages were associated with poorer survival in OSCC patients. This result is compatible with other studies showing that patients with OSCC are commonly diagnosed late, a fact that negatively influences their prognosis (16,25). This late diagnosis has been attributed to factors such as the absence of initial symptoms, the patient’s lack of knowledge about the disease, and the fear of diagnosis. Moreover, a late diagnosis can be associated with the lack of access to specialized services or diagnostic failure in primary care, exposing flaws in the health care system (26). In Brazil, although the implementation of health policies has expanded the access to oral health services and favored opportunistic screening for oral cancer, failures in early cancer detection by dental professionals are still common (27).

This fact highlights the need to reinforce relevant basic knowledge about the prevention and early diagnosis of oral cancer throughout the undergraduate dental course and the adoption of continued educational strategies for professionals (28).

A single therapeutic modality was associated with lower survival rates in this study compared to the use of combination therapies. These results are similar to other studies, which found a better prognosis when adjuvant radiotherapy or chemotherapy was used after surgical treatment (20). Some authors observed that patients who were treated surgically, with or without the use of adjuvant therapy, had a much longer survival time than those not submitted to any surgical intervention (29). Since surgery is mostly indicated for smaller tumors, these findings reinforce the importance of an early diagnosis, as patients with advanced-stage inoperable tumors can only receive radio/chemotherapy as palliative treatment, worsening their prognosis (20,29).

In the current study, there was no association between survival outcomes and anatomical site of the tumor. However, lower survival rates have been related to neoplasms located at the base of the tongue and oropharynx. Locoregional metastasis was found to be more frequent in these cases due to the significant lymphatic vascularization in the region, with a consequent poorer prognosis (6). Moreover, some anatomical sites are challenging for diagnosis and treatment and can influence tumor progression and prognosis. In this respect, the lip region is more accessible, facilitating early detection and diagnosis and resulting in better survival rates (16).

No association between the presence of comorbidities and survival time was found in this study. However, the presence of comorbidities has been reported as an important factor in assessing the survival of patients with oral cancer, as the time required to investigate and monitor these other diseases can lead to delay in antineoplastic treatment (30). In addition, depending on the type and severity of the comorbidity, therapeutic modalities such as surgical resection may be contraindicated, negatively impacting patient prognosis (17). The frequency of comorbidities was considered low in the sample studied.
The main limitation of the current study is the use of secondary data, which may be associated with incomplete or incorrect medical records. However, given the robust statistical analysis, these limitations are unlikely to compromise our results. The data of this study refer to a considerable sample size and a long observation period, providing important evidence of factors associated with the prognosis of OSCC patients, which is a crucial field of study in public health.

**Conclusions**

Advanced clinical stage, younger age at diagnosis, and single treatment predict poorer survival in patients diagnosed with OSCC. These findings encourage further research on factors that could modify disease outcomes in patients with OSCC.

**References**

1. De Paz D, Kao HK, Huang Y, Chang KP. Prognostic stratification of patients with advanced oral cavity squamous cell carcinoma. Curr Oncol Rep. 2017;19:65.
2. Bosetti C, Carroli G, Santucci C, Bertuccio P, Gallus S, Garavello W, et al. Global trends in oral and pharyngeal cancer incidence and mortality. Int J Cancer. 2020;147:1040–104.
3. Faria SO, Nascimento MCD, Kulcsar MAV. Malignant neoplasms of the oral cavity and oropharynx treated in Brazil: what do hospital cancer records reveal?. Braz J Otorhinolaryngol. 2020;81:808–809.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
5. Sasahira T, Kiritu T. Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma. Int J Mol Sci. 2018;19:2413.
6. Juhn P, Dittmann J, Zimmerer R, Stier R, Juhn M, Gefrich NC, et al. Survival rates according to tumour location in patients with surgically treated oral and oropharyngeal squamous cell carcinoma. Anticancer Res. 2019;39:2527–33.
7. Listl S, Jansen I, Stenzinger A, Freier K, Emrich K, Holleczek et al. Survival of patients with oral cavity cancer in Germany. PLoS One. 2013;8:e53415.
8. Brandwein-Gensler M, Smith RV. Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol. 2010;4:53–61.
9. Moro JS, Maroneze MC, Ardemigh TM, Barin LM, Danesi CC. Oral and oropharyngeal cancer: epidemiology and survival analysis. Einstein (Sao Paulo). 2018;16:1-5.
10. Frare JC, Sawazaki-Calone A, Ayroza-Rangel AL, Bueno AG, Morais CF, Nagai HM, et al. Histopathological grading systems analysis of oral squamous cell carcinomas of young patients. Med Oral Patol Oral Cir Buca. 2016;21:e285-98.
11. Cariati P, Cabello-Serrano A, Perez-de Perceval-Tara M, Mon-salve-Iglesias F, Martinez-Lara I. Oral and oropharyngeal squamous cell carcinoma in young adults: A retrospective study of Granada University Hospital. Med Oral Patol Oral Cir Buca. 2017;22:e679-85.
12. Soudry E, Preis M, Hod R, Hamzany Y, Hadar T, Bahar G et al. Squamous cell carcinoma of the oral tongue in patients younger than 30 years: clinicopathologic features and outcome. Clin Otolaryngol. 2010;35:307-12.
13. Santos-Silva AR, Ribeiro ACP, Souhia AMP, Miyahara GI, Carlos R, Speight PM, et al. High incidences of DNA ploidy abnor-

malties in tongue squamous cell carcinoma of young patients: an international collaborative study. Histopathology. 2011;58:1127-35.
14. Hilly O, Shked Y, Hod R, Soudry E, Mizrahi A, Hamzany Y, et al. Carcinoma of the oral tongue in patients younger than 30 years: comparison with patients older than 60 years. Oral Oncol. 2013;49:987-90.
15. Tomo S, Neto SC, Collado FU, Sundeinfeld ML, Bernabé DG, Bisoló ER, et al. Head and neck squamous cell carcinoma in young patients: a 26-year clinicopathologic retrospective study in a Brazilian specialized center. Med Oral Patol Oral Cir Buca. 2020;25:e416-24.
16. Asio J, Kamulegeya A, Banura C. Survival and associated factors among patients with oral squamous cell carcinoma (OSCC) in Mulago hospital, Kampala, Uganda. Cancers Head Neck. 2018;3:9.
17. Katna R, Kalyani N, Agarwal S, Singh S, Deshpande A, Bhosale B. Impact of comorbidities on perioperative outcomes for carcinoma of oral cavity. Ann R Coll Surg Engl. 2019;00:1–4.
18. De Santis S, Spinosi MC, Cambi J, Bengalca C, Bocuzzi S. Oropharyngeal squamous cell carcinoma and HPV. Systematic review on overall management. J Stomatol Oral Maxillofac Surg. 2017;118:103-108.
19. Agarwal AK, Sethi A, Sardeen D, Dhingra S. Treatment delay in oral and oropharyngeal cancer in our population: the role of socioeconomic factors and health-seeking behaviour. Indian J Otolaryngol Head Neck Surg. 2011;63:145–50.
20. Le Campion ACOV, Ribeiro CMB, Luiz RR, Silva Júnior FF, Barros HCS, Santos KCB, et al. Low Survival Rates of Oral and Oropharyngeal Squamous Cell Carcinoma. Int J Dent. 2017;2017:58154931.
21. Ghani WMN, Ramanathan A, Prime SS, Yang YH, Razak IA, Rahman ZAA, et al. Survival of oral cancer patients in different ethnicities. Cancer Invest. 2019;37:275-87.
22. Antunes JLF, Toporcov TN, Biazevic MGH, Boing AF, Bastos JL. Gender and racial inequalities in trends of oral cancer mortality in Sao Paulo, Brazil. Rev Saude Publica. 2013;47:470-478.
23. Osazuwa-Peters N, Massa TA, Christopher KM, Walker RJ, Varvares MA. Race and sex disparities in long-term survival of oral and oropharyngeal cancer in the United States. J Cancer Res Clin Oncol. 2016;142:521-28.
24. Megwatu UC, Ma Y. Racial disparities in oropharyngeal cancer stage at diagnosis. Anticancer Res. 2017;37:835-40.
25. Lifšics A, Rate E, Ivanova A, Tars J, Murovska M, Groma V. Survival analysis of oropharyngeal squamous cell carcinoma patients linked to histopathology, disease stage, tumor stage, risk factors, and received therapy. Exp Oncol. 2020;42:51-9.
26. Coca-Pelaz A, Takes RP, Hutcheson K, Saba NF, Haigentz M, Bradford CR, et al. Head and neck cancer: a review of the impact of treatment delay on outcome. Adv Ther. 2018;35:153–60.
27. Cunha AR, Prass TS, Hugo FN. Mortality from oral and oropharyngeal cancer stage at diagnosis. Cancer Res. 2017;8:1–5.
28. Cunha AR, Prass TS, Hugo FN. Mortality from oral and oropharyngeal cancer in Brazil: impact of the National Oral Health Policy. Cad Saude Publica. 2019;35:e00014319.
29. Noro LRA, Landim JR, Martins MCA, Lima YCP. The challenge of the approach to oral cancer in primary health care. Cien Saude Colet. 2017;22:1579-87.
30. Ong TK, Murphy C, Smith AB, Kanatasa AN, Mitchell DA. Survival after surgery for oral cancer: a 30-year experience. Br J Oral Maxillofac Surg. 2011;55:911-916.
31. Cunha AR, Prass TS, Hugo FN. Mortality from oral and oropharyngeal cancer in Brazil: impact of the National Oral Health Policy. Cad Saude Publica. 2019;35:e00014319.
32. Noro LRA, Landim JR, Martins MCA, Lima YCP. The challenge of the approach to oral cancer in primary health care. Cien Saude Colet. 2017;22:1579-87.
33. Ong TK, Murphy C, Smith AB, Kanatasa AN, Mitchell DA. Survival after surgery for oral cancer: a 30-year experience. Br J Oral Maxillofac Surg. 2011;55:911-916.
34. Corkin-Pelaz A, Takes RP, Hutcheson K, Saba NF, Haigentz M, Bradford CR, et al. Head and neck cancer: a review of the impact of treatment delay on outcome. Adv Ther. 2018;35:153–60.
35. Cunha AR, Prass TS, Hugo FN. Mortality from oral and oropharyngeal cancer in Brazil: impact of the National Oral Health Policy. Cad Saude Publica. 2019;35:e00014319.
Ethics
This study received approval from the Human Research Ethics Committee of the State University of Paraíba (Brazil) (Approval number 21852513300005187).

Authors contributions
Conception and planning of the study: Godoy GP, Granville-Garcia AF, Carvalho SHG, Sarmento DJ, Agrípino GG. Data acquisition: Carvalho SHG. Data analysis and interpretation: Ferreira AKA, Abreu MNHG, Carvalho SHG, Godoy GP. Manuscript preparation and editing: Ferreira AKA, Carvalho SHG, Caldas Jr AF, Godoy GP, Melo MCF. Critical revision of the article: Godoy GP, Caldas Jr AF, Agrípino GG, Granville-Garcia AF, Melo MCF, Sarmento DJ. Final approval of the article: Ferreira AKA, Abreu MNHG, Agrípino GG, Caldas Jr AF, Carvalho SHG, Godoy GP, Granville-Garcia AF, Melo MCF, Sarmento DJ.